Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide.

Christopher L McDonaldKeir JohnsonDaniel AlsoofJanine MolinoMariah Balmaceno-CrissAlan H Daniels

Published in: The Journal of the American Academy of Orthopaedic Surgeons (2023)

Teriparatide and abaloparatide can safely be used for osteoporosis and orthopaedic perioperative management without increased risk of development of primary bone malignancy.

Keyphrases

bone mineral density
postmenopausal women
body composition
patients undergoing